Previous Close | 0.3500 |
Open | 0.0000 |
Bid | 0.3350 x N/A |
Ask | 0.0000 x N/A |
Day's Range | 0.3500 - 0.3500 |
52 Week Range | 0.2000 - 0.7800 |
Volume | |
Avg. Volume | 29,752 |
Market Cap | 153.013M |
Beta (5Y Monthly) | 2.87 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
NORWOOD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the first quarter ended March 31, 2024. “With the first quarter now in the books, I’m pleased to say we are on track with our strategic plan and financial targets,” said Jon Levine, Chief Executive Officer. “The tremendous growth in our wholesale business was un
NORWOOD, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- The following is a statement from Jon Levine, CEO and President of leading multi-state cannabis operator, MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD). “The impending announcement of the DEA’s decision to recategorize cannabis from Schedule I to Schedule III under the Controlled Substances Act is historic. The positive impact this will have cannot be overstated. Our industry, the millions of consumers and patients we serve, and the individ
NORWOOD, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced the closing of its acquisition of Allgreens Dispensary, LLC on April 9, 2024. The approval of the license transfer by the Illinois Department of Financial & Professional Regulation, and subsequent closing of the acquisition, allows MariMed to fully consolidate the financial results of the Company’s Thr